TapewireFind a company

person · Reporting owner

Birznieks Gunther

Disclosed activity across 1 company

Tapewire entity
62821
SEC CIK
0001702031

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Vanda Pharmaceuticals Inc.VNDA · Entity 5861SVP, Business DevelopmentMarch 02, 2026March 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Vanda Pharmaceuticals Inc.

Report date March 02, 2026 · Filed March 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect494,197 Reported balance After 2026-03-02 transaction · row 1
1 source row

Row 1 · 2026-03-02 · Sale · Disposed 42,431 · Balance 494,197

F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 02, 2026 Filed Mar 4, 2026 18:51 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 42,431 $8.27 $350,730.40
Disclosure

SEC source: 0001702031-26-000002 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 494,197

F1 · shares: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 18, 2026 Filed Feb 19, 2026 17:51 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 125,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-059784 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 536,628

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 16:46 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 Tax withholdingCommon Stock 26,941 $4.76 $128,239.16
Disclosure

SEC source: 0000950170-25-032281 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 411,628

F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs.

Read SEC document
February 18, 2025 Filed Feb 20, 2025 19:44 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 125,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-024486 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 438,569

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
March 05, 2024 Filed Mar 6, 2024 16:46 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,684 $4.13 $35,884.02
Disclosure

SEC source: 0000950170-24-027249 · ownership.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,569

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.1306 to $4.1339, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 16:46 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,727 $4.30 $37,494.68
Disclosure

SEC source: 0000950170-24-027249 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,253

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.28 to $4.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 16:50 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 125,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-018024 · ownership.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,980

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
March 03, 2023 Filed Mar 6, 2023 18:24 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,268 $6.26 $51,790.75
Disclosure

SEC source: 0001209191-23-016460 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,980

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2301 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 02, 2023 Filed Mar 6, 2023 18:24 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,509 $6.20 $52,793.24
Disclosure

SEC source: 0001209191-23-016460 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,248

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.1901 to $6.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 16, 2023 Filed Feb 21, 2023 18:08 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantStock Option (Right to Buy) · Derivative 77,500 $0.00 Strike: $7.05 $0.00
Disclosure

SEC source: 0001209191-23-011338 · doc4.xml · derivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2033-02-15

F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Read SEC document
February 16, 2023 Filed Feb 21, 2023 18:08 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 32,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-011338 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,757

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
August 26, 2022 Filed Aug 29, 2022 17:02 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 1,250 $0.00 Strike: $3.12 $0.00
Disclosure

SEC source: 0001209191-22-047887 · doc4.xml · derivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250 shares

Expires 2022-12-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested in 48 equal monthly installments beginning on December 7, 2012.

Read SEC document
August 26, 2022 Filed Aug 29, 2022 17:02 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 Exercise / conversionCommon Stock 1,250 $3.12 $3,900.00
Disclosure

SEC source: 0001209191-22-047887 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 02, 2022 Filed Mar 2, 2022 21:26 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 11,517 $11.27 $129,791.98
Disclosure

SEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 3

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,807

F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $11.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 01, 2022 Filed Mar 2, 2022 21:26 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 4,084 $11.19 $45,699.96
Disclosure

SEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,324

F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 21:26 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantStock Option (Right to Buy) · Derivative 77,500 $0.00 Strike: $11.36 $0.00
Disclosure

SEC source: 0001209191-22-015154 · doc4.xml · derivative · entry 4

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2032-02-27

F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 21:26 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 32,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,408

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 18:39 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 16,620 $18.19 $302,272.93
Disclosure

SEC source: 0001209191-21-017272 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,708

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 18:39 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 3,845 $18.66 $71,743.86
Disclosure

SEC source: 0001209191-21-017272 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,328

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.53 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 17:15 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantEmployee Stock Option (Right to Buy) · Derivative 77,500 $0.00 Strike: $20.28 $0.00
Disclosure

SEC source: 0001209191-21-014869 · doc4.xml · derivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2031-02-23

F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 17:15 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 32,700 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-014869 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,173

F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
March 03, 2020 Filed Mar 4, 2020 17:00 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 5,535 $10.66 $58,984.28
Disclosure

SEC source: 0001209191-20-016197 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,473

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.8644, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 17:00 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 12,223 $10.04 $122,685.92
Disclosure

SEC source: 0001209191-20-016197 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,008

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 26, 2020 Filed Feb 28, 2020 18:01 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantEmployee Stock Option (Right to Buy) · Derivative 70,000 $0.00 Strike: $11.32 $0.00
Disclosure

SEC source: 0001209191-20-014124 · doc4.xml · derivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2030-02-25

F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Read SEC document
February 26, 2020 Filed Feb 28, 2020 18:01 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-014124 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,231

F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
January 02, 2020 Filed Jan 6, 2020 17:25 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 4,020 $15.93 $64,021.31
Disclosure

SEC source: 0001209191-20-002027 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,231

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to a written election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
March 04, 2019 Filed Mar 4, 2019 17:02 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,788 $19.89 $174,766.96
Disclosure

SEC source: 0001209191-19-015731 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,251

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
March 01, 2019 Filed Mar 4, 2019 17:02 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 3,741 $20.14 $75,325.04
Disclosure

SEC source: 0001209191-19-015731 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,039

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 to $20.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 16:18 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantEmployee Stock Option (Right to Buy) · Derivative 70,000 $0.00 Strike: $20.62 $0.00
Disclosure

SEC source: 0001209191-19-014962 · doc4.xml · derivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2029-02-26

F2 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments from the date of grant, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 16:18 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-014962 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,780

F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2020, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
January 03, 2019 Filed Jan 4, 2019 16:34 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 1,619 $26.09 $42,231.62
Disclosure

SEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 3

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,780

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

Read SEC document
January 02, 2019 Filed Jan 4, 2019 16:34 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 1,170 $26.95 $31,527.99
Disclosure

SEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,399

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
January 02, 2019 Filed Jan 4, 2019 16:34 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 3,272 $26.30 $86,050.33
Disclosure

SEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,569

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.87 to $26.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
March 01, 2018 Filed Mar 2, 2018 17:32 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,525 $18.72 $159,605.05
Disclosure

SEC source: 0001209191-18-015872 · doc4.xml · nonDerivative · entry 2

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,841

F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F3 · price: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:32 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantEmployee Stock Option (Right to Buy) · Derivative 70,000 $0.00 Strike: $18.85 $0.00
Disclosure

SEC source: 0001209191-18-015872 · doc4.xml · derivative · entry 3

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2028-02-27

F4 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.

Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:32 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 GrantCommon Stock 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-015872 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,366

F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Read SEC document
January 02, 2018 Filed Jan 4, 2018 17:09 UTC Vanda Pharmaceuticals Inc. VNDA · Entity 5861 SaleCommon Stock 8,568 $15.26 $130,776.81
Disclosure

SEC source: 0001209191-18-002050 · doc4.xml · nonDerivative · entry 1

Birznieks Gunther · CIK 0001702031 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,366

F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.